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and intrathecal colistin
Multidrug-resistant Pseudomonas aeruginosa,1,2
defined on the basis of resistance to all commer-
cially available antibiotics, is an important cause of
nosocomial infections. Many of these P. aeruginosa
strains show in vitro susceptibility only to colistin,3
an old antibiotic that was used in the past to treat
cases of meningitis.4,5 Herein, we present a case of
multidrug-resistant P. aeruginosameningitis suscep-
tible only to colistin, treated successfully with intra-
venous and intrathecal colistin.
A 35 year-old female with a history of systemic
lupus erythematosus (SLE) was admitted to the
hospital due to an acute episode of fever, productive
cough and pancytopenia. SLE had been diagnosed
seven years previously when she presented with
peripheral neuropathy, seizures and cervical myelo-
pathy. For the past three years she had been taking
prednisolone (10 mg/day) and azathioprine (50 mg/
day).
The patient was successfully treated with anti-
biotics, filgrastim, intravenous immunoglobulin and
prednisolone (1 mg/kg/day, iv), and was about to
leave hospital when on the ninth day, she developed
persistent fever of unknown origin. On the sixteenth
day, while still febrile, she developed headache,
neck stiffness, confusion, weakness of her right leg
and abnormal plantar response. The non-contrast
CT scan of the brain showed a small sub-arachnoid
hemorrhage (SAH) in both the frontal lobes. Lumbar
puncture showed pleocytosis establishing the diag-
nosis of meningitis.
Due to her history of CNS complications, the
patient was treated for three days with methyl-
prednisolone (1 g/day, iv) and cyclophosphamide
(750 mg bolus, iv), as well as with ceftriaxone (2 g
q12h, iv) plus gentamicin (80 mg q8h, iv). Three
days later the cerebrospinal fluid (CSF) culture grew
amultidrug-resistant P. aeruginosa, susceptible only
to colistin (MIC = 4 mg/L) and to an in vitro combi-
nation of ceftazidime with amikacin.1201-9712/$32.00 # 2005 International Society for Infectious DiseasThe treatment was changed to intravenous
colistin (colistin sodium methane sulfonate,
Rhone—Poulenc Rorer, 1 000 000 IU q8h), ceftazi-
dime (2 g q8h, iv), amikacin (500 mg q12h, iv),
and intrathecal infusions of colistin through an
intrathecal catheter (Table 1).
On the fourth day of treatment, the patient
developed numbness of her left arm and the dose
of intrathecal colistin was decreased. Soon after the
initiation of this treatment, the patient’s clinical
condition improved and CSF culture was found to be
negative.
On the thirteenth day of treatment, she relapsed
and CSF culture grew Enterococcus faecalis, a
possible superinfection admitted through the
intrathecal catheter; this catheter was replaced.
Intravenous vancomycin (500 mg q6h), rifampin
(600 mg/day, po), and intrathecal vancomycin were
added to the treatment (Table 1). Treatment with
intravenous colistin was maintained for a total of 30
days and the patient was finally cured.
P. aeruginosa infections of CNS include meningitis
and brain abscesses. Although current data suggest
that ceftazidime is the antibiotic of choice for
P. aeruginosa meningitis6 the increasing incidence
of infections caused by multidrug-resistant P. aeru-
ginosa strains1,2 susceptible only to polymyxins, has
forced their use to be reconsidered.
Colistin, polymyxin E, interacts strongly with
phospholipids and penetrates into, and disrupts,
the structure of cell membranes.3 Its use was cur-
tailed when second- and third-generation cephalos-
porins became available, mainly because of toxicity.
It was used intravenously or intrathecally to treat
CNS infections even in newborns and children.5
Nowadays there is an increasing body of pub-
lished reports about colistin’s use for the treatment
of multidrug-resistant infections caused by Gram-
negative rods such as P. aeruginosa and Acinetobac-
ter baumannii.7—9 The evidence suggests that
further studies are needed to clarify colistin’s phar-
macokinetic and pharmacodynamic properties as no
modern pharmacokinetic studies of polymyxins have
yet been published.10es. Published by Elsevier Ltd. All rights reserved.
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Table 1 Intrathecal infusion regimen.
Day of treatment Regimen, dose
Day 1 Colistin 20 000 IU
Day 2 Colistin 40 000 IU
Day 3 Colistin 60 000 IU
Day 4 Colistin 60 000 IU
Days 5—15 Colistin 30 000 IU
Days 16, 18, 20,
22, 24, 26
Colistin 60 000 IU plus
Vancomycin 20 mgIn this case, intravenous and intrathecal colistin
infusions were tolerated well and without any ser-
ious adverse effects. The intrathecal infusion regi-
men was decided according to the company’s
recommendations, with some necessary modifica-
tions due to early signs of reversible neurotoxicity.
One year later the patient is very well, with no
residual neurological manifestations.
In conclusion, intravenous and intrathecal colis-
tin may be a good therapeutic option in the treat-
ment of meningitis due to multidrug-resistant P.
aeruginosa.
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doi:10.1016/j.ijid.2005.03.005ken in our country, however, there have been no
studies on the prevalence of brucellosis in Kayseri.
This cross-sectional research was performed on 1850
individuals living in the Kayseri rural region in 2001.
People aged from 15 to 85 in nine districts were
interviewed, and blood samples were screened by
the Rose Bengal test.4
In our study, 3.4% of the total 1850 people were
found to be positive for Brucella (Table 1). The pre-
